Is EXACT SCIENCES CORP (EXAS) Halal?

NASDAQ Healthcare United States $20.0B
✓ HALAL
Confidence: 95/100
EXACT SCIENCES CORP (EXAS) is Halal under 3 of 5 Shariah screening standards, including AAOIFI Standard 21. With a debt ratio of just 12.8% against the AAOIFI threshold of 30%, EXACT SCIENCES CORP comfortably passes the key financial ratio tests. The company operates in the Healthcare sector (Diagnostics & Research), which is not a prohibited industry under Islamic finance principles.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 12.8%
/ 30%
4.9%
/ 30%
1.5%
/ 30%
1.06%
/ 5%
✓ HALAL
DJIM 12.8%
/ 33%
4.9%
/ 33%
1.5%
/ 33%
1.06%
/ 5%
✓ HALAL
MSCI 43.0%
/ 33%
16.5%
/ 33%
5.1%
/ 33%
1.06%
/ 5%
✗ NOT HALAL
S&P 12.8%
/ 33%
4.9%
/ 33%
1.5%
/ 33%
1.06%
/ 5%
✓ HALAL
FTSE 43.0%
/ 33%
16.5%
/ 33%
5.1%
/ 50%
1.06%
/ 5%
✗ NOT HALAL

Financial Highlights

EPS
$-1.10
P/B Ratio
8.3
EV/EBITDA
302.2
EV: $21.6B
Revenue
$3.2B
Growth: 23.1%
Beta
1.4
High volatility
Current Ratio
2.4

Profitability

Gross Margin 69.7%
Operating Margin -9.3%
Net Margin -6.4%
Return on Equity (ROE) -8.7%
Return on Assets (ROA) -1.6%

Cash Flow & Balance Sheet

Operating Cash Flow$491M
Free Cash Flow$357M
Total Debt$2.5B
Debt-to-Equity105.6
Current Ratio2.4
Total Assets$5.9B

Price & Trading

Last Close$104.91
50-Day MA$103.11
200-Day MA$75.68
Avg Volume2.5M
Beta1.4
52-Week Range
$38.81
$104.98

About EXACT SCIENCES CORP (EXAS)

Employees
7,100
Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Exchange
NASDAQ
Market Cap
$20.0B
Currency
USD

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Purification Calculator

As a halal stock with 1.06% impermissible income, you need to purify your dividends.

Enter your dividends to calculate purification amount

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is EXACT SCIENCES CORP (EXAS) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), EXACT SCIENCES CORP is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is EXACT SCIENCES CORP's debt ratio?

EXACT SCIENCES CORP's debt ratio is 12.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 43.0%.

Does EXACT SCIENCES CORP require dividend purification?

Yes, EXACT SCIENCES CORP has an impermissible income ratio of 1.06%, which means 1.06% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.

What are EXACT SCIENCES CORP's key financial metrics?

EXACT SCIENCES CORP has a market capitalization of $20.0B, and revenue of $3.2B. The company maintains a gross margin of 69.7% and a net margin of -6.4%. Return on equity stands at -8.7%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.